Atlas Trials

Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Clinical trial NCT06563869 · RECRUITING

Trial details

NCT number
NCT06563869
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Esophageal Squamous Cell Carcinoma
Start date
2024-02-02
Primary completion
2025-11-22
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.